2021
DOI: 10.1016/j.jadohealth.2020.05.032
|View full text |Cite
|
Sign up to set email alerts
|

Awareness and Willingness to Use Biomedical Prevention Strategies for HIV Among Sexual and Gender Minority Youth: Results From a National Survey

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 20 publications
(3 citation statements)
references
References 22 publications
0
3
0
Order By: Relevance
“…This suggests that efforts to reduce PrEP out-of-pocket costs, in isolation of the other tradeoffs patients consider, may not be effective to increase interest in PrEP. Surveys have shown that many young GBMSM are not even aware of PrEP [ 27 ], so targeted messaging efforts by public health officials about the safety and efficacy of PrEP may be the best way to increase PrEP uptake among high-risk youth and others unfamiliar with PrEP, especially given the importance of low out-of-pocket costs for PrEP among young GBMSM [ 28 ]. Among those not reporting interest in PrEP, there was no single attribute that stood out as being most important to increase interest in PrEP among that group.…”
Section: Discussionmentioning
confidence: 99%
“…This suggests that efforts to reduce PrEP out-of-pocket costs, in isolation of the other tradeoffs patients consider, may not be effective to increase interest in PrEP. Surveys have shown that many young GBMSM are not even aware of PrEP [ 27 ], so targeted messaging efforts by public health officials about the safety and efficacy of PrEP may be the best way to increase PrEP uptake among high-risk youth and others unfamiliar with PrEP, especially given the importance of low out-of-pocket costs for PrEP among young GBMSM [ 28 ]. Among those not reporting interest in PrEP, there was no single attribute that stood out as being most important to increase interest in PrEP among that group.…”
Section: Discussionmentioning
confidence: 99%
“…Stigma is a major barrier to PrEP initiation among BMSM who may anticipate and/or encounter negative experiences with healthcare providers, such as being labelled as “promiscuous” when attempting to obtain PrEP [ 6 , 25 , 26 ]. Recent studies reported that BMSM are less likely to access PrEP and less likely to disclose their sexual identity and sexual behaviors to healthcare professionals due to stigma [ 16 , 22 , 27 , 28 ]. HIV-related stigma is high in the South, and PrEP could be associated with HIV risk or an HIV-positive status, which furthers create barriers for uptake [ 8 , 26 , 29 ].…”
Section: Bmsm Prep Uptake In the Southmentioning
confidence: 99%
“…The use of antiretrovirals for PrEP is a safe and highly effective method that has been demonstrated through multiple clinical trials to prevent HIV [ 3 , 6 , 14 , 15 ]. The U.S. Food and Drug Administration (FDA) has approved the use of Truvada (tenofovir disoproxil fumarate/emtricitabine) and Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) for PrEP to prevent HIV, with both medications clinically indicated for use among MSM [ 6 , 16 ]. Despite the benefits of PrEP, evidence indicates there is poor uptake of PrEP across the U.S., especially among BMSM [ 3 , 5 , 7 , 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%